recombinant human EGF-rP64K/Montanide ISA 51 vaccine

{
  "id": "MLC-T-ONC-016414",
  "term": "recombinant human EGF-rP64K/Montanide ISA 51 vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.",
  "abbreviation": "CimaVax",
  "synonyms": [
    "CimaVax vaccine",
    "Center of Molecular Immunology (CIMA) epidermal growth factor (EGF) vaccine",
    "Center of Molecular Immunology epidermal growth factor vaccine",
    "CIMAvax-EGF",
    "CIMAvax EGF",
    "CIMAvax epidermal growth factor vaccine",
    "recombinant human EGF-P64K/Montanide vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/recombinant-human-egf-rp64k-montanide-isa-51-vaccine/"
}